IP Library Granted Patent US 9,371,360
Granted Patent B2
US 9,371,360 · App. 14/362,011 · Granted Jun 21, 2016

Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (PSMA) and uses thereof

Inventors: Martin Gilbert Pomper (Baltimore, MD); Sangeeta Ray (Ellicott City, MD); Ronnie C. Mease (Fairfax, VA); Hassan Shallal (Baltimore, MD)
Assignee: THE JOHNS HOPKINS UNIVERSITY
C07K5/0821A61K38/06A61K45/06A61K51/088C07D249/04C07K5/0217C07K5/0815A61K51/0482
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,371,360
App. No.
14/362,011
Granted
Jun 21, 2016
Kind
B2
Abstract

The present invention provides bivalent and multivalent ligands with a view to improving the affinity and pharmacokinetic properties of a urea class of PSMA inhibitors. The compounds and their synthesis can be generalized to multivalent compounds of other target antigens. Because they present multiple copies of the pharmacophore, multivalent ligands can bind to receptors with high avidity and affinity, thereby serving as powerful inhibitors. The modular multivalent scaffolds of the present invention, in one or more embodiments, contains a lysine-based (α-, ε-)dialkyne residue for incorporating two or more antigen binding moieties, such as PSMA binding Lys-Glu urea moieties, exploiting click chemistry and one or more additional lysine residues for subsequent modification with an imaging and/or therapeutic nuclides or a cytotoxic ligands for tumor cell killing.

Claims (11)

1. A compound of formula II:

wherein Z is H, CO 2 H, NH 2 , SH and OH;

wherein R 1 is the same or different moiety and is selected from the group consisting of:

and

alternatively, R 1 is a peptide ligand to an enzyme or endothelial receptor; and

wherein R 2 is a chelating moiety, a fluorescent dye or H, wherein when R 2 is a chelating moiety, it can be bound to a metal ion useful in imaging, or as a cytotoxic moiety;

or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

2. A pharmaceutical composition comprising a compound, salt, solvate, or stereoisomer of claim 1 , and a pharmaceutically acceptable carrier.

3. A pharmaceutical composition comprising a compound, salt, solvate, or stereoisomer of claim 1 , and at least one or more other biologically active agents.

4. A pharmaceutical composition comprising a compound, salt, solvate, or stereoisomer of claim 1 , and at least one or more other anticancer compounds.

5. A method of imaging prostate cancer in a subject comprising administering to the subject an effective amount of a compound, salt, solvate, or stereoisomer of claim 1 , or pharmaceutical compositions thereof, wherein R 2 is chelating moiety bound to a metal ion useful in imaging, or fluorescent dye.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2014
From: POMPER, MARTIN GILBERT; RAY, SANGEETA; MEASE, RONNIE C.; SHALLAL, HASSAN
To: THE JOHNS HOPKINS UNIVERSITY
Reel/Frame 033956/0778 →
Continuity (2)
Provisional Application 61565179 · Nov 30, 2011
Related Publication 20140341804A1 · Nov 20, 2014